Topcon Medical Systems, Inc.
Paramus, NJ, October 1, 2009 –Topcon Medical Systems, Inc. announced that it has received 510(k) marketing clearance by the Food and Drug Administration for its new 3D OCT‐2000 system.
A successor of the 3D OCT‐1000, which has sold over 1,500 units worldwide, the 3D OCT‐2000 further enhances the users’ ability to image and visualize large areas of the macula and the optic nerve in high‐resolution on the integrated color touch screen display. Automated 3D OCT capture and fundus capture technology ensures fast office workflow and requires minimal staff training to operate.
In addition to a new instrument platform, the 3D OCT‐2000 incorporates enhanced registration and noise reduction software to provide outstanding OCT B Scan and 3D images.
The all‐in‐one instrument integrates a non‐mydriatic color fundus camera with a high‐resolution Nikon D‐90 12.3‐megapixel sensor that can detect and display retinal abnormalities hidden from OCT imaging, from small hemangiomas to retinal hemhorrages and white patches, in high, blur‐free image quality. This combination of technology also enables the user to take sequential stereo disc color photos.
With Topcon’s FastMap™ software, images captured using the 3D OCT‐2000 can be viewed and compared with simultaneous dynamic visualization of OCT, fundus and thickness map imaging for both eyes on the same screen or on serial exams from the same eye. The software can also be used to create 2D and 3D videos. The 3D OCT‐2000 features Pin‐Point™ Registration of OCT and fundus imaging, and its compare function allows serial monitoring of captured images.
The instrument can be integrated within a clinical or academic network and is fully networkable with EMRs and Topcon’s EyeRoute® Ophthalmic Image Management System. The integration of 3D OCT and a digital fundus imaging in a single compact device reduces costs and consumes minimal office space, and also features user‐friendly touch‐screen operation.
Topcon’s VP of Marketing, Katrin Teigeler, sees the launch of the 3D OCT‐2000 as another step forward in helping to better diagnose and manage retinal diseases. “The 3D OCT 2000 was designed to provide the benefits needed in a real‐world clinical practice. It unites superb image quality and high performance with unique practical features to improve workflow while providing deep diagnostic insights.”
The system will be officially launched at the Retina Congress in New York (September 30 – October 4) and Vision Expo West in Las Vegas (September 30 – October 3) and Topcon plans to ship the first units in early November 2009.
About Topcon Medical Systems, Inc.
Based in Paramus, NJ, Topcon Medical Systems (TMS) is a leader and technical innovator in the field of ophthalmic instrumentation. For over 37 years, TMS has offered the most complete and technically advanced line of ophthalmic equipment in the US marketplace. This equipment comprises the largest selection of precision ophthalmic and optical instruments from one manufacturer, providing a complete range of products for general and specialized applications. TMS manages ophthalmic dealer sales, corporate sales, and the Advanced Technology Products Division. TMS is a division of Topcon America Corporation, a wholly owned subsidiary of Topcon Corporation of Tokyo, Japan.